Title Category Credit Event datesort ascending Cost
Traversing New Terrains In CLL: The Emerging Role Of BTK Inhibitors In The Treatment Landscape
  • Oncology
  • ANCC
  • Participation
12/09/2020 $0.00 The objective of this activity is to provide evidence-based information on the latest developments for the use of Bruton’s tyrosine kinase (BTK) inhibitors in patients with chronic lymphocytic leukemia (CLL). Given the demonstrated clinical benefit of BTKi therapy and its advantages over chemotherapy, it is essential for patients that the adoption of BTKi therapy continues to accelerate. Optimizing patient adherence to oral BTKis is vital to achieving efficacy and improving clinical outcomes.
Traversing New Terrains In CLL: The Emerging Role Of BTK Inhibitors In The Treatment Landscape
  • Oncology
  • ANCC
  • Participation
11/19/2020 $0.00 The objective of this activity is to provide evidence-based information on the latest developments for the use of Bruton’s tyrosine kinase (BTK) inhibitors in patients with chronic lymphocytic leukemia (CLL). Given the demonstrated clinical benefit of BTKi therapy and its advantages over chemotherapy, it is essential for patients that the adoption of BTKi therapy continues to accelerate. Optimizing patient adherence to oral BTKis is vital to achieving efficacy and improving clinical outcomes.
Adaptive Protocols and Practical Strategies for the Use of Novel Anticoagulation Reversal Agents
  • Cardiology
  • AAPA Category I CME
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • ICPE
11/10/2020 $0.00 This interprofessional, community Grand Rounds initiative is targeted to addressing the professional practice of physicians, pharmacists, nurse practitioners, physician assistants, nurses, and other healthcare professionals, who manage patients who are taking anticoagulation therapy, and who may require reversal agents for direct oral anticoagulants to address acute bleeding complications.
Revolutionizing Outcomes in Gynecologic Surgery: The Pivotal Role of Iron Deficiency Anemia
  • AAPA Category I CME
  • AMA PRA Category 1 Credit™
  • ANCC
11/09/2020 $0.00 Iron deficiency anemia is a far-reaching condition of immense clinical impact in women’s health, with implications ranging from the global, epidemiological scale, to treatment by individual OB/GYNs and gynecologic surgeons, and most importantly, to individual patient outcomes. As such, this educational initiative is designed to address the myriad challenges of iron deficiency anemia (IDA) in women’s health using a dynamic, multifaceted approach targeted to OB/GYNs and gynecologic laparoscopists.
Betting on BTK Inhibitors in CLL: Where are We Now and Where are We Going?
  • Oncology
  • ACPE Pharmacy
  • Participation
11/04/2020 $0.00 This initiative is targeted to addressing the professional practice of pharmacists in hospitals, health systems, ambulatory care clinics, and other settings. Attendees of this activity will gain insight into the latest clinical and scientific advances in the treatment and management of patients with chronic lymphocytic leukemia (CLL) using BTK inhibitors (BTKis), including the latest approvals, the most current safety and efficacy data, and expert insights into addressing challenges of CLL treatment using BTKis.
Betting on BTK Inhibitors in CLL: Where are We Now and Where are We Going?
  • Oncology
  • ACPE Pharmacy
  • Participation
10/29/2020 $0.00 This initiative is targeted to addressing the professional practice of pharmacists in hospitals, health systems, ambulatory care clinics, and other settings. Attendees of this activity will gain insight into the latest clinical and scientific advances in the treatment and management of patients with chronic lymphocytic leukemia (CLL) using BTK inhibitors (BTKis), including the latest approvals, the most current safety and efficacy data, and expert insights into addressing challenges of CLL treatment using BTKis.
Traversing New Terrains In CLL: The Emerging Role Of BTK Inhibitors In The Treatment Landscape
  • Oncology
  • ANCC
  • Participation
10/28/2020 $0.00 The objective of this activity is to provide evidence-based information on the latest developments for the use of Bruton’s tyrosine kinase (BTK) inhibitors in patients with chronic lymphocytic leukemia (CLL). Given the demonstrated clinical benefit of BTKi therapy and its advantages over chemotherapy, it is essential for patients that the adoption of BTKi therapy continues to accelerate. Optimizing patient adherence to oral BTKis is vital to achieving efficacy and improving clinical outcomes.
Betting on BTK Inhibitors in CLL: Where are We Now and Where are We Going?
  • Oncology
  • ACPE Pharmacy
  • Participation
10/24/2020 $0.00 This initiative is targeted to addressing the professional practice of pharmacists in hospitals, health systems, ambulatory care clinics, and other settings. Attendees of this activity will gain insight into the latest clinical and scientific advances in the treatment and management of patients with chronic lymphocytic leukemia (CLL) using BTK inhibitors (BTKis), including the latest approvals, the most current safety and efficacy data, and expert insights into addressing challenges of CLL treatment using BTKis.
Navigating a Changing Landscape in TNBC: Pharmacist-Focused Strategies in the Era of Immunotherapy
  • Oncology
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • Participation
10/20/2020 $0.00 Symposium attendees will gain insights into the molecular heterogeneity and diverse clinical features of TNBC, a condition which comprises 15-20% of all breast cancer cases, and has historically had limited treatment options, been associated with earlier age of onset, more aggressive disease course, and poorer prognosis.
Putting NSCLC to the Test: Oncology Nurse Perspectives in the Era of Precision Medicine
  • Oncology
  • ANCC
  • Participation
10/20/2020 $0.00 Attendees will gain an appreciation of the latest advances in non-small cell lung cancer (NSCLC), including the nurse’s role in comprehensive biomarker testing strategies and biomarker-driven treatment approaches. Expert faculty will reflect on the lung cancer tumor board, with emphasis on the appropriate selection of targeted therapy based on patient- and biomarker-specific factors in oncogenic driver mutations.

Pages